2024-03-28T12:50:19Zhttps://eprints.lib.hokudai.ac.jp/dspace-oai/requestoai:eprints.lib.hokudai.ac.jp:2115/546712022-11-17T02:08:08Zhdl_2115_20044hdl_2115_124Regulation of multidrug resistance protein 2 (MRP2, ABCC2) expression by statins: Involvement of SREBP-mediated gene regulationKobayashi, MasakiGouda, KeisukeChisaki, IkumiAsada, KojiOgura, JiroTakahashi, NatsukoKonishi, ToruKoshida, YusukeSasaki, ShotaroYamaguchi, HiroakiIseki, KenStatinHepatocytesMultidrug resistance protein 2Sterol regulatory element-binding protein499Multidrug resistance protein 2 (MRP2, ABCC2) is localized to the apical membrane of hepatocytes and played an important role in the biliary excretion of a broad range of endogenous and xenobiotic compounds and drugs, such as pravastatin. However, the effects of statins on MRP2 in the liver and the precise mechanisms of their actions have been obscure. The goal of this study was to determine the regulatory molecular mechanism for statin-induced MRP2 expression in hepatocytes. In vitro and in vivo studies suggested that pitavastatin increased MRP2 expression. Pitavastatin promoted liver X receptor (LXR) alpha/beta translocation from the cytosol to nuclei, resulting in LXR activation. Deletion and mutational analysis suggested that the potential sterol regulatory element (SRE) played a major role in the observed modulation of MRP2 expression by pitavastatin. Furthermore pitavastatin increased the protein-DNA complex, and when SRE was mutated, stimulation of the protein-DNA complex by pitavastatin was decreased. It was demonstrated that pitavastatin upregulated MRP2 expression by an SREBP regulatory pathway in hepatocytes and that the actions of statins may lead to improve the biliary excretion of MRP2 substrates. (C) 2013 Elsevier B.V. All rights reserved.Elsevier science bvJournal Articleapplication/pdfhttp://hdl.handle.net/2115/54671https://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/54671/1/WoS_62834_Kobayashi.pdf0378-5173International journal of pharmaceutics4521-236412013-08-16enginfo:pmid/23612356info:doi/10.1016/j.ijpharm.2013.04.019author